Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Nacuity Pharmaceuticals Inc. is managing 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 6 actions are handled by 5 distinct examiners across 5 distinct art units. Amy C Bonaparte is the busiest examiner, with 2 of the 6 pending actions currently under their review.
The fact that 5 examiners are assigned to 6 actions means that most examiners are only handling a single case for the company. This distribution across 5 art units indicates that the pending matters cover several different technical specialties within the biotechnology field. Practitioners must manage the 2 actions assigned to Amy C Bonaparte while addressing the unique requirements of the other examiners. The involvement of 5 distinct art units requires a prosecution approach that can adapt to the specific standards of multiple technical departments. With 6 pending actions, the company maintains a diverse but focused portfolio in the Biotechnology & Pharmaceuticals sector. The presence of the examiners ensures that a variety of perspectives are applied to the review of these innovations.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (75%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BONAPARTE, AMY C | 2 | 79.1% | +23.5% |
| KIM, DANIELLE A | 1 | 36.6% | +51.9% |
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18770850 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 14d |
| 18678550 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 14d |
| 17701051 | TREATMENT OF FERROPTOSIS | CHONG, YONG SOO | 60d |
| 19539174 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF, AND TABLETS THEREOF | KIM, DANIELLE A | — |
| Art Unit | Apps |
|---|---|
| 1692 | 2 |
| 1613 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19539174 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF, AND TABLETS THEREOF | KIM, DANIELLE A | 1613 | §103§112DP | Non-Final OA | — | Pending | Feb 13, 2026 |
| 18770850 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 1692 | §103 | Final Rejection | 14d | Pending | Jul 12, 2024 |
| 18678550 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 1692 | §103 | Final Rejection | 14d | Pending | May 30, 2024 |
| 17701051 | TREATMENT OF FERROPTOSIS | CHONG, YONG SOO | 1623 | §103 | Final Rejection | 60d | Pending | Mar 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNacuity Pharmaceuticals Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Amy C Bonaparte has the most, with 2 of Nacuity Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
